Yüksel Ürün/X
Mar 31, 2025, 11:43
Yüksel Ürün: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, posted on X:
“BREAKING from NEJM.
In cancer patients with Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is:
- Noninferior to full-dose (5 mg BID) for VTE recurrence.
- Lower bleeding risk (12.1% vs. 15.6%).
- Safer extended anticoagulation, same protection.”
Jennifer A. Marks, Thoracic Oncologist at Georgetown Lombardi, shared this post on X, adding:
“Finally, the data for cancer-associated VTE is here! Despite some of us already doing this in other settings, I’m thankful to see this literature!”
“Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.”
Authors: Isabelle Mahé et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 9, 2025, 02:00
Jun 8, 2025, 17:03
Jun 8, 2025, 16:53